Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Age-Related Macular Degeneration Publisher



Pour EK1 ; Bazvand F1 ; Iyer S2 ; Khojasteh H1 ; Roohipourmoallai R3 ; Hajizadeh F4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Ophthalmology, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Ophthalmology, University of Florida College of Medicine, Gainesville, FL, United States
  3. 3. Department of Ophthalmology, Morsani College of Medicine, University of South Florida, Tampa, FL, United States
  4. 4. Noor Ophthalmology Research Center, Noor Eye Hospital, No. 96, Esfandiar Blvd, Vali’asr Ave, Tehran, Iran

Source: Atlas of Ocular Optical Coherence Tomograph# Second Edition Published:2023


Abstract

Age-related macular degeneration (AMD) is the leading cause of legal blindness in the elderly. Optical coherence tomography (OCT) is the most frequently used technique for the diagnosis and follow-up of AMD patients, and it is widely used to investigate and guide the therapeutic strategy, as well as anticipate and analyze treatment effects. OCT gives critical information on both dry and wet-type AMD like atrophic retinal changes, pigmented epithelial detachment, serous retinal detachments, hemorrhages, and subretinal neovascular membranes and enables for a more accurate and extensive study of anatomic structures and neovascular membrane lesions subtypes. The goal of this chapter is to discuss several structural OCT-based indicators that may be used during both the initial evaluation and follow-up of AMD patients. OCT technology is continuously evolving, and new retinal signs and biomarkers are being disclosed on a regular basis. This chapter provides an updated and extensive discussion of how structural OCT-based biomarkers might be utilized to assess disease progression and therapy response in individuals with AMD. © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.